Filtered By:
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 6987 results found since Jan 2013.
Evaluation of a viral transcriptome Next Generation Sequencing assay as an alternative to animal assays for viral safety testing of cell substrates
Vaccine. 2023 Jul 17:S0264-410X(23)00831-9. doi: 10.1016/j.vaccine.2023.07.019. Online ahead of print.ABSTRACTThe viral safety of biological products is ensured by tests throughout the production chain, and, for certain products, by steps in the manufacturing process enabling the elimination or inactivation of viruses. Current testing programs include sample inoculation in animals and embryonic eggs. Following the 3Rs principles of replacement, reduction, and refinement of animal-use methods, such techniques are intended to be replaced not only for ethical reasons but also because of their inherent technical limitations, t...
Source: Vaccine - July 19, 2023 Category: Allergy & Immunology Authors: Pascale Beurdeley-Fehlbaum Matthew Pennington Nicolas H égerlé M élanie Albert Amy Bennett Justine Cheval Allison Clark St éphane Cruveiller C éline Desbrousses Janalyn Frederick Edwige Gros Kathryn Hunter Tareq Jaber Madison Gaiser Oph élie Jouffro Source Type: research
Long-term monitoring of immune response to recombinant lumpy skin disease virus in dairy cattle from small-household farms in western Thailand
This study elucidated immune responses in dairy cattle herd affected by recombinant LSDV.PMID:37467568 | DOI:10.1016/j.cimid.2023.102008
Source: Comparative immunology, microbiology and infectious diseases. - July 19, 2023 Category: Allergy & Immunology Authors: Nutthakarn Suwankitwat Kultyarat Bhakha Lamul Molee Tapanut Songkasupa Kanokwan Puangjinda Tapakorn Chamchoy Orapun Arjkumpa Bandit Nuansrichay Smit Srisomrun Phitcha Pongphitcha Porntippa Lekcharoensuk Pipat Arunvipas Source Type: research
Evaluation of a viral transcriptome Next Generation Sequencing assay as an alternative to animal assays for viral safety testing of cell substrates
Vaccine. 2023 Jul 17:S0264-410X(23)00831-9. doi: 10.1016/j.vaccine.2023.07.019. Online ahead of print.ABSTRACTThe viral safety of biological products is ensured by tests throughout the production chain, and, for certain products, by steps in the manufacturing process enabling the elimination or inactivation of viruses. Current testing programs include sample inoculation in animals and embryonic eggs. Following the 3Rs principles of replacement, reduction, and refinement of animal-use methods, such techniques are intended to be replaced not only for ethical reasons but also because of their inherent technical limitations, t...
Source: Vaccine - July 19, 2023 Category: Allergy & Immunology Authors: Pascale Beurdeley-Fehlbaum Matthew Pennington Nicolas H égerlé M élanie Albert Amy Bennett Justine Cheval Allison Clark St éphane Cruveiller C éline Desbrousses Janalyn Frederick Edwige Gros Kathryn Hunter Tareq Jaber Madison Gaiser Oph élie Jouffro Source Type: research
Induced protection from a CCHFV-M DNA vaccine requires CD8 < sup > + < /sup > T cells
Virus Res. 2023 Jul 15:199173. doi: 10.1016/j.virusres.2023.199173. Online ahead of print.ABSTRACTCrimean-Congo hemorrhagic fever (CCHF) is a World Health Organization prioritized disease because its broad distribution and severity of disease make it a global health threat. Despite advancements in preclinical vaccine development for CCHF virus (CCHFV), including multiple platforms targeting multiple antigens, a clear definition of the adaptive immune correlates of protection is lacking. Levels of neutralizing antibodies in vaccinated animal models do not necessarily correlate with protection, suggesting that cellular immun...
Source: Virus Research - July 17, 2023 Category: Virology Authors: Joseph W Golden Collin J Fitzpatrick John J Suschak Tamara L Clements Keersten M Ricks Mariano Sanchez-Lockhart Aura R Garrison Source Type: research
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate
Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.07.008. Online ahead of print.ABSTRACTThe continuing high global incidence of COVID-19 and the undervaccinated status of billions of persons strongly motivate the development of a new generation of efficacious vaccines. We have developed an adjuvanted vaccine candidate, PHH-1V, based on a protein comprising the receptor binding domain (RBD) of the Beta variant of SARS-CoV-2 fused in tandem with the equivalent domain of the Alpha variant, with its immunogenicity, safety and efficacy previously demonstrated in mouse models. In the present study, we immun...
Source: Vaccine - July 17, 2023 Category: Allergy & Immunology Authors: Alexandra Moros Antoni Prenafeta Antonio Barreiro Eva Perozo Alex Fern ández Manuel Ca ñete Luis Gonz ález Carme Garriga Edwards Pradenas Silvia Marfil Juli à Blanco Paula Cebollada Rica Marta Sister é-Oró Andreas Meyerhans Teresa Prat Caba ñas Ric Source Type: research
Fight Aging! Newsletter, July 17th 2023
In conclusion, the longevity-associated genotype of FLT1 may confer increased lifespan by protecting against mortality risk posed by hypertension. We suggest that FLT1 expression in individuals with longevity genotype boosts vascular endothelial resilience mechanisms to counteract hypertension-related stress in vital organs and tissues.
Resistance Exercise Slows the Onset of Pathology in a Mouse Model of Alzheimer's Disease
https://www.fightaging.org/archives/2023/07/resistance-exercise-slows-the-onset-of-pathology-in-a-mouse-model-of-alzheimers-disease/
With the caveat that mouse models of Alzheimer's...
Source: Fight Aging! - July 16, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The association between rLiHyp1 protein plus adjuvant and amphotericin B is an effective immunotherapy against visceral leishmaniasis in mice
In this study, we evaluated an immunotherapy protocol in a murine model by combining recombinant (r)LiHyp1 (a hypothetical amastigote-specific Leishmania protein protective against Leishmania infantum infection), with monophosphoryl-lipid A (MPLA) as adjuvant and amphotericin B (AmpB) as reference antileishmanial drug. We used this protocol to treat L. infantum infected-BALB/c mice, and parasitological, immunological and toxicological evaluations were performed at 1 and 30 days after treatment. Results showed that mice treated with rLiHyp1/MPLA/AmpB presented the lowest parasite burden in all organs evaluated, when both a ...
Source: Acta Tropica - July 15, 2023 Category: Infectious Diseases Authors: Daniela P Lage V ívian T Martins Danniele L Vale Camila S Freitas Breno L Pimenta Gabriel J L Moreira Fernanda F Ramos Isabela A G Pereira Raquel S Bandeira Marcelo M de Jesus Fernanda Ludolf Grasiele S V Tavares Miguel A Ch ávez-Fumagalli Bruno M Roatt Source Type: research
Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
Antiviral Res. 2023 Jul 12:105670. doi: 10.1016/j.antiviral.2023.105670. Online ahead of print.ABSTRACTThe hepatitis E virus (HEV) is a major cause of hepatitis, with an estimated 3.3 million symptomatic cases annually. There is no HEV-specific treatment besides the off-label use of ribavirin and a vaccine is only available in China and Pakistan. To aid the development of therapeutic and preventive strategies, there is a need for convenient HEV infection models in small laboratory animals. To this end, we make use of the rat hepatitis E virus. Human infections with this virus have been reported in recent years, making it a...
Source: Antiviral Research - July 14, 2023 Category: Virology Authors: Xin Zhang Niels Cremers Stijn Hendrickx Yannick Debing Tania Roskams Lotte Coelmont Johan Neyts Suzanne J F Kaptein Source Type: research
An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms
Eur J Med Chem. 2023 Jul 7;258:115629. doi: 10.1016/j.ejmech.2023.115629. Online ahead of print.ABSTRACTThe current Coronavirus Disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is highly contagious infection that breaks the healthcare systems of several countries worldwide. Till to date, no effective antiviral drugs against COVID-19 infection have reached the market, and some repurposed drugs and vaccines are prescribed for the treatment and prevention of this disease. The currently prescribed COVID-19 vaccines are less effective against the newly emergent varian...
Source: European Journal of Medicinal Chemistry - July 12, 2023 Category: Chemistry Authors: Biswanath Dinda Manikarna Dinda Subhajit Dinda Utpal Chandra De Source Type: research
